Partnership of cardiologists with gene transfer therapy prescribers is essential to identifing patient-specific considerations that might influence risk for adverse cardiac events.
What: Poster Session When: Friday, October 11 from 2:15-3:15 pm Dystrophinopathy in ACTION; Analysis of the first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective
29th Annual Congress of World Muscle Society- ACTION Abstracts Poster Session Read More »
Abstract Advanced Cardiac Therapies Improving Outcomes Network (ACTION) and Pediatric Heart Transplant Society (PHTS) convened a working group at the beginning of 2020 during the COVID-19 pandemic, with the aim
The results of an ACTION-wide survey of pediatric cardiology providers are detailed in the latest ACTION publication, Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD):
ACTION receives $2 million grant from Parent Project Muscular Dystrophy (PPMD) to expand muscular dystrophy focused research and quality improvement initiatives
IMPROVING STROKE OUTCOMES IN CHILDREN SUPPORTED WITH A VENTRICULAR ASSIST DEVICE IN A QUALITY IMPROVEMENT NETWORK ACTION has been working to reduce the frequency of stroke associated with pediatric VAD
ABCs of Stroke Prevention Read More »
This ACTION article, published in Pediatric Transplantation, describes the results of ACTION’s November 2019 Waitlist Outcomes Committee (WOC) meeting. The WOC committee used improvement science methodology to develop a six-step
A coordinated approach to improving pediatric heart transplant waitlist outcomes Read More »
A MULTICENTER REGISTRY ANALYSIS The HeartMate 3™ LVAD was originally designed for use in adults with heart failure. This study, published in the Journal of Heart and Lung Transplantation on
"*" indicates required fields
Copyright © 2024 Advanced Cardiac Therapies Improving Outcomes Network
